Qualy #106 - Does LDL cause heart disease?

Episode Summary

Executive Summary: This episode reviews a European Atherosclerosis Society consensus statement arguing that LDL is causal in atherosclerosis and heart disease, supported by epidemiology, genetics, Mendelian randomization, and intervention data. The discussion also emphasizes nuance: LDL-lowering is not uniformly beneficial in every context, and LDL particle number—not just LDL cholesterol—matters mechanistically.

Main Topics: LDL causality and heart disease (Priority: 5/5): The central topic is whether LDL is a causal factor in atherosclerosis, not merely an associated marker. The speakers frame the consensus statement as a comprehensive rebuttal to claims that LDL is a myth or non-causal. Evidence base for causality (Priority: 5/5): The paper synthesizes multiple lines of evidence—epidemiology, clinical trials, genetics, and Mendelian randomization—using classic causality criteria such as plausibility, strength, dose-response, temporality, consistency, and intervention effects. Familial hypercholesterolemia and genetic natural experiments (Priority: 5/5): Familial hypercholesterolemia and PCSK9-related genetic variants are highlighted as especially strong evidence that lifelong LDL elevation causes premature cardiovascular disease. Nuance and heterogeneity in LDL-lowering benefit (Priority: 4/5): The conversation stresses that lowering LDL is not always beneficial in every population or under every intervention, and that this does not invalidate LDL causality; it reflects biological and clinical heterogeneity. LDL cholesterol vs LDL particles (Priority: 4/5): The speakers distinguish LDL cholesterol concentration from LDL particle number, noting that cholesterol levels do not always mirror particle burden, which is more directly tied to atherogenicity. Mechanism of LDL metabolism and receptor-mediated clearance (Priority: 4/5): The discussion explains how the liver produces, recycles, and clears cholesterol, with LDL receptors binding ApoB-containing particles as a key disposal pathway targeted by many lipid-lowering drugs. Publication context and follow-up paper (Priority: 3/5): The first consensus statement was published in early 2018, and a second paper focused on LDL’s role in atherosclerosis pathophysiology was described as still in progress.

Key Arguments: LDL is causal in heart disease, not merely correlated with it; the consensus statement assembled multiple independent evidence streams to support this. Genetic evidence is the strongest line of support: people with familial hypercholesterolemia or PCSK9 variants demonstrate that lifelong LDL elevation leads to atherosclerosis and early cardiovascular events. Mendelian randomization and natural experiments strengthen causal inference because they approximate randomized exposure differences over a lifetime. Lowering LDL is generally beneficial, but not universally so; some populations or interventions may not show reduced risk, which reflects heterogeneity rather than disproving causality. The relevant causal entity is often the LDL particle burden, not just LDL cholesterol concentration, because cholesterol values do not always track particle number. Most LDL-lowering therapies work by increasing LDL receptor-mediated clearance of ApoB-containing particles, reinforcing the mechanistic link between LDL metabolism and disease risk.

Data Points: Consensus statement publication timing: Early 2018 - The first European Atherosclerosis Society consensus statement was published in early 2018. Causality criteria discussed: 8 criteria - The paper addressed plausibility, strength, biological gradient, temporal sequence, specificity, consistency, coherence, and intervention-related risk reduction. Paper structure: 2-part series - The work was planned as two papers: one on causality evidence and another on LDL’s role in atherosclerosis pathophysiology. Podcast release schedule: Tuesday through Friday each week - The host notes that new Qualies episodes are released Tuesday through Friday for members. Severe FH example: 8- or 9-times normal cholesterol - An example was given of an eight-year-old child with cholesterol levels eight or nine times normal, illustrating extreme genetic causality.

Pivotal Quotes: "does LDL cause heart disease? Is LDL a causal factor for heart disease?" — Interviewer: Introduces the central scientific question addressed by the consensus statement. "all you have to do is look at an eight-year-old child with cholesterol levels that are eight or nine times normal... to know that that's it. That's causal." — Speaker: Uses familial hypercholesterolemia as a vivid example of direct causality. "Just because lowering LDL cholesterol is not always beneficial doesn't mean that LDL is not pathological." — Speaker: Clarifies that exceptions to treatment benefit do not negate LDL’s causal role.

Implications: For listeners and clinicians, the takeaway is that LDL remains a validated causal target in cardiovascular prevention, but interpretation should be nuanced: particle burden, genetics, and patient context matter. The debate is less about whether LDL matters and more about how best to measure and modify it.